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Why are the small airways important in the pathology and 
treatment of asthma? Asthma is an inflammatory disorder 
of the airways often associated with structural 
abnormalities and progressive decline in lung function. 
Successful therapy therefore requires efficacious drug 
delivery to these airways. Traditionally, inhaled asthma 
therapies have mainly targeted the large airways of the 
lung. There is increasing evidence, however, of 
inflammation and chronic structural changes within the 
small airways in patients with asthma, and thus it is 
pertinent that the therapeutic targets for inhaled 
corticosteroids are reconsidered to take into account all 
of the pulmonary tissues that may respond to inhaled 
anti-inflammatory treatment. 
The challenge now lies in evaluating the value of the 
small airways as therapeutic targets in asthma. The articles 
in this supplement critically assess the evidence for 
inflammatory and structural changes in the airways of 
patients with asthma, recent technical advances in the 
monitoring of inflammation, and the clinical efficacy of 
topical corticosteroids and how this may relate to their 
ability to target the small airways. 
As the small airways normally contribute only about 
10% of airway resistance (the ‘quiet zone’), the difficulty of 
in riro sampling and physiological measurements that are 
specific for this site has led to their considerable 
under-evaluation (I). However, techniques such as 
transbronchial biopsy, along with the analysis of resected 
lung tissue and post-mortem tissue, have demonstrated that 
extensive disease exists in the small airways. Airway 
remodelling, potentially leading to a component of fixed 
airflow obstruction, has also been shown to occur in the 
small airways (2). Fibroblast proliferation and collagen 
deposition may also contribute to this permanent tissue 
damage (3,4). 
In contrast to conventional pulmonary function tests, 
which lack specificity for small airways, recent advances in 
high-resolution computed tomography imaging have 
allowed non-invasive reproducible measurements of 
structure-function relationships in the small airways and 
in viva assessment of drug deposition (5,6). This method, 
although providing indirect data of air trapping and 
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hyperinflation as an indication of small airways 
obstruction, is a step forward from the standard approach 
of planar imaging (7). 
Inefficient drug delivery systems have long been accepted, 
providing they produce a clinical response. Recent 
evidence, however, indicates that inflammation of the lung 
persists in those patients treated with corticosteroids that 
are deposited only in the central large airways (8), 
highlighting the need for the optimization of drug delivery 
to the small airways. Chronic poorly controlled 
inflammation in the peripheral airways may contribute to 
the observed accelerated decline in lung function with 
age (9) and, notably, in patients with newly diagnosed 
asthma (10). Furthermore, delayed or inadequate anti- 
inflammatory treatment may allow deleterious airway 
remodelling to take place, resulting in permanent loss of 
lung function (11-14). 
Recently published data from a 15-year follow-up of the 
Copenhagen Heart Study has highlighted the extent of 
FEV, decline over time in adults with asthma (15). This 
decrease in FEV, was significantly greater among subjects 
with asthma than among those without the disease 
(PcO*OOl), regardless of smoking history, although smok- 
ing, as anticipated, significantly accelerated the decline in 
FEVi. Such findings support the perception of ongoing 
tissue injury and repair associated with asthma which may 
reduce distensibility of the lungs and adversely affect lung 
function (14). 
From the evidence that inflammatory and structural 
changes occur throughout the airways, it is clear that 
anti-inflammatory treatment_ needs to be directed at both 
the large ahd small airways to achieve suppression of 
inflammation throughout the entire bronchial tree. 
Enhanced drug deposition can be achieved with the aid of 
improved technology. However, not all metered-dose 
inhalers (MDIs) and dry-powder inhalers are necessarily 
efficient at specifically depositing medication in the 
peripheral airways of the lung. 
Even with optimal inhalation technique only 10% of the 
steroid dose generated by chloroflurocarbon (CFC)-based 
MDIs reaches the lower respiratory tract, with most of the 
medication deposited in the oropharynx (16). However, 
new propellants have been researched and developed 
following the decision to discontinue the use of CFCs. 
For example, beclomethasone dipropionate (BDP) has been 
reformulated in hydrofluroalkane- 134a (HFA) propellant 
(QVARTM; 3M Pharmaceuticals, St Paul, MN, U.S.A.). 
0 2000 HAR~~IJRTPUE~LISHERS LTD 0954-6111/00/ODOOOS1+02 $35-00/O 
S2 J. Bou~uzr 
Due tb improved inhaler technology, this MD1 produces an 
extrafine aerosol of medication. As the particle size of 
HFA-BDP (1.1 pm) is three times smaller than that with the 
conventional CFC-BDP formulation, approximately 60% 
of the inhaled dose is deposited in the lungs (17). 
Furthermore, improved drug delivery to the small airways 
is achieved as the drug enters the lungs with uniform 
distribution (18). As a greater proportion of drug is 
distributed in the lungs, lower doses can be used to achieve 
an equivalent clinical response to conventional CFC-based 
corticosteroid inhalers. 
Clearly, the small airways are an important therapeutic 
target for inhaled corticosteroids which cannot be 
overlooked. If we are going to make a positive long-term 
impact on the function and structure of the airways in 
asthma, we need to be committed to providing inhaled 
therapies that are distributed throughout the airways, both 
centrally and pehpherally, to maximize both the efficacy 
and safety of these treatments. 
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